Practical and ethical advantages of Bayesian approaches in adaptive clinical trial designs. Kristian Thorlund
|
|
- Cornelius White
- 5 years ago
- Views:
Transcription
1 Practical and ethical advantages of Bayesian approaches in adaptive clinical trial designs Kristian Thorlund
2 Background This talk was previously given as an invited talk at a DSEN sponsored meeting on innovative clinical trials designs, Jan , Ottawa 2
3 Background Health care is moving towards an era with a growing number of patient sub-populations that are rare and difficult to study in clinical trials Within Canada, there is a very high demand for clinical trial methodologists that can think beyond the conventional parallel design RCT 3
4 Objectives Generate a healthy debate on how to move forward and be innovative, yet conscientious, about trial designs in Canada Illustrate the type of thinking that may be required for trial designs in challenging populations 4
5 Outline Teaser Bayesian stereotypes and efficiency reflections Introduction to Bayesian analysis Introduction to Adaptive designs Illustrative example: hepatitis C 5
6
7
8
9 ECMO trials Phase I - CMT: 4/10 deaths; ECMO: 0/9 deaths Phase II ECMO 1/10 death Within the scientific literature this was criticized on both sides No patients should have been randomized to CMT Not enough patients were randomized to CMT Was O Rourke s approach a breaking point? 4 babies deaths was all the staff could take
10
11
12 Traditional hierarchy of evidence RCTs & Systematic reviews Cohort Studies Case-series Clinical expert opinions 12
13 In small populations Observational studies RCTs and SRs expert opinion 13
14 In small populations Highly Efficient Study Design Not so efficient study design 14
15 Bayesian Statistics Are Bayesian statistics the answer? when and how? 15
16 Concepts of Bayesian Statistics (gross oversimplification) Bayesian analysis is unique for allowing data to be mixed with prior (external) evidence or opinions. By contrast, the conventional Frequentist discipline of statistics is only data driven 16
17 Bayesian Stereotypes Not fully data driven Too complex Hard to trust due to subjectivity Goes against conventional EBM Too philosophical Buzz word.. Used by the cool statisticians Incorporates evidence of lower quality 17
18 Bayesian Stereotypes Please forget these stereotypes! Bayesian analysis is flexible it can be what you want, need and/or require of it to be Easy or complex Rigorous or exploratory Objective or subjective Broad or narrow 18
19 In small populations Highly Efficient Study Design Not so efficient study design 19
20 In small populations Bayesian Adaptive Designs Conventional parallel design RCTs 20
21 Concepts of Bayesian Statistics (gross oversimplification) Bayesian analysis is unique for allowing data to be mixed with prior (external) evidence or opinions. By contrast, the conventional Frequentist discipline of statistics is only data driven 21
22 Bayesian Statistical Inferences Priors take the form of probability distributions, and are mixed with the likelihood to shape a posterior probability distribution from which inferences are drawn Frequentist drawn inferences solely from the likelihood (but necessitates parametric distributional assumptions) 22
23 Bayesian priors Available data from RCTs (e.g. response to Tx) Drug A vs Drug B Difference in response 23
24 Bayesian priors + external data: clinical expert survey/obs. study Drug A vs Drug B Difference in response 24
25 Bayesian posterior distributions Adding the two together forms a posterior distribution 25
26 Bayesian philosophy (again gross oversimplification) Bayesians try to answer given the data, what are the likely effects and degrees of uncertainty Frequentist try to answer how likely are the estimated treatment effects to be observed in a study attempting to replicate the current data? 26
27 Bayesian thinking and adaptive designs Considering the underlying philosophies, Bayesian statistics and adaptive clinical trials seem to go hand in hand. Frequentist methods in adaptive clinical trials are conceptually counter-intuitive. Note: many researchers apply frequentist methods, but Bayesian thinking (without knowing it) 27
28 Adaptive designs Adaptive designs typically allow for flexible change in randomization ratio or elimination of treatment groups after interim analyses 28
29 Adaptive designs For example, a trial examining placebo, low dose, mid dose, and high dose, may start with 1:1:1:1 randomisation, but gradually randomise more and more to higher doses based on better observed responses in the mid and high dose arms This is Bayesian thinking relying only on data, or in other words, non-informed Bayesian statistics (i.e., employed priors are non-informative) 29
30 Adaptive designs Consider the placebo, low, mid, high dose example. After data is available for 200 patients, you make a decision on whether to change the 1:1:1:1 randomisation ratio 30
31 Adaptive designs Assume you see the following responses. What would your new randomization ratio be? 23/50 20/49 11/49 5/52 Placebo Low Dose Mid Dose High Dose 31
32 Adaptive designs Placebo Low dose Mid dose High Dose 50 patients/arm 100 patients/arm 32
33 Adaptive designs Placebo Low dose Mid dose High Dose 50 patients/arm 100 patients/arm 33
34 Adaptive designs Placebo Low dose Mid dose High Dose 50 patients/arm 100 patients/arm 34
35 Bayesian thinking in rare diseases No major design challenges in larger populations However, most diseases in pediatrics and rare populations are both rare and trialist face several difficulties enrolling a large number of patients 35
36 Adaptive designs in pediatrics Typically only a few centers (e.g., SickKids hospitals) can enroll patients and this limits the number of feasible candidate patients compared with adult trials Adapting to small numbers is prone to errors by the play of chance. Thus, without innovative twists these designs typically have little value for informing clinical practice 36
37 Adaptive designs in pediatrics Consider again a trial that starts with 1:1:1:1 randomisation to placebo, low, mid, and high dose. Say you can feasibly only enroll 50 patients over the trial period of 3 years. That is, no more than 50 patients will be available for any clinical study over the next 3 years. How realible is randomisation adjustments then half-way through? How useful it is? (pros and cons?) 37
38 Adaptive designs Which adjustments would be comfortable with the following numbers? 2/6 3/5 3/6 1/7 Placebo Low Dose Mid Dose High Dose 38
39 Adaptive designs You only have 26 patients left and need to make the most our of the evidence. 2/6 3/5 3/6 1/7 Placebo Low Dose Mid Dose High Dose 39
40 Adaptive designs What is external evidence on the same trial population was available on placebo? 3/5 3/6 2/6 3/19 4/35 1/7 External Evidence on Placebo Placebo Low Dose Mid Dose High Dose 40
41 Adaptive designs How many more patients do we need to randomise to placebo with this evidence? 3/5 3/6 2/6 3/19 4/35 1/7 External Evidence on Placebo Placebo Low Dose Mid Dose High Dose 41
42 Conventional vs Bayesian Adaptive Consider two scenarios 1. We ignore the external evidence and keep randomising 1:1:1:1 2. We include the external placebo evidence, stop randomizing to placebo and randomise 1:1:1 with the three doses 42
43 Scenario #1 Maintain 1:1:1:1 randomisation, no statisticallly significant difference detected 4/12 6/11 7/14 2/13 Placebo Low Dose Mid Dose High Dose P=
44 Scenario #2 Stop randomising to placebo 9/17 9/18 6/18 3/19 4/35 1/7 External Evidence on Placebo Placebo Low Dose Mid Dose High Dose 44
45 Scenario #1 versus Scenario #2 #1 Placebo Response P=0.11 Mid Dose Response 0% 10% 20% 30% 40% 50% 60% 70% 80% #2 Placebo Response Evidence P>0.05 0% 10% 20% 30% 40% 50% 60% 70% 80% 45
46 Scenario #1 versus Scenario #2 #1 Placebo Response P=0.11 Mid Dose Response 0% 10% 20% 30% 40% 50% 60% 70% 80% Posterior Placebo Response #2 P<0.05 0% 10% 20% 30% 40% 50% 60% 70% 80% 46
47 Motivating example - HCV An increasing number of highly potent agents are available for treating hepatitis C in adults Conventional therapy, peginterferon+ribavirin is known to eradicate the virus children at the same rate as in adults and have similar or better safety profile than in adults (Druyts et al CID 2012, systematic review of 8 trials) 47
48 Motivating example - HCV Some of the most potent newer direct acting agents (DAAs) eradicate the virus in 90% of adults without co-administration of interferon (and are thus more safe) How are these agents likely to work in children? Can they reduce adverse events (e.g., anemia)? Can they avoid reduction in growth? 48
49 Motivating example - HCV Expected efficacy 90% 80-90% 50% Peg-Riba DAA+ Peg-Riba DAA 49
50 Motivating example - HCV Choosing the randomisation scheme n? n? n? Peg-Riba DAA+ Peg-Riba DAA 50
51 Motivating example - HCV Choosing the randomisation scheme n? n? 50% n? Peg-Riba External Evidence Peg-Riba DAA+ Peg-Riba DAA 51
52 Motivating example - HCV Expected safety (anemia, neutropenia, rash, ) 20% 20% 25% 10% Peg-Riba External Evidence Peg-Riba DAA+ Peg-Riba DAA 52
53 Motivating example - HCV Expected safety (anemia, neutropenia, rash, ) 20% n? n? n? Peg-Riba External Evidence Peg-Riba DAA+ Peg-Riba DAA 53
54 Motivating example - HCV Bayesian adaptive design: Borrows strength from systematic review to stop placebo randomization Could also borrow strength from adult population (confirm signal) Stop early for benefit/safety based on Bayesian significance 54
55 This is where we started Not fully data driven Too complex Hard to trust due to subjectivity Goes against conventional EBM Too philosophical Buzz word.. Used by the cool statisticians Incorporates evidence of lower quality 55
56 Hopefully this is where we are going Incorporates all relevant evidence Allows for transparent analysis Takes the step into the era beyond EBM Sufficiently flexible Helps us think about efficiency Only used by the cool statisticians (same as before) 56
57 THANK YOU! 57
MS&E 226: Small Data
MS&E 226: Small Data Lecture 10: Introduction to inference (v2) Ramesh Johari ramesh.johari@stanford.edu 1 / 17 What is inference? 2 / 17 Where did our data come from? Recall our sample is: Y, the vector
More informationAppraising the Literature Overview of Study Designs
Chapter 5 Appraising the Literature Overview of Study Designs Barbara M. Sullivan, PhD Department of Research, NUHS Jerrilyn A. Cambron, PhD, DC Department of Researach, NUHS EBP@NUHS Ch 5 - Overview of
More informationHierarchy of Statistical Goals
Hierarchy of Statistical Goals Ideal goal of scientific study: Deterministic results Determine the exact value of a ment or population parameter Prediction: What will the value of a future observation
More informationOverview of Study Designs in Clinical Research
Overview of Study Designs in Clinical Research Systematic Reviews (SR), Meta-Analysis Best Evidence / Evidence Guidelines + Evidence Summaries Randomized, controlled trials (RCT) Clinical trials, Cohort
More informationOutline. Basic principles of lung protective ventilation. The challenging areas. Small tidal volumes Recruitment
ARDS beyond 6/kg Gordon D. Rubenfeld, MD MSc Professor of Medicine, University of Toronto Chief, Program in Trauma, Emergency, and Critical Care Sunnybrook Health Sciences Centre Outline Basic principles
More informationResearch in Real-World Settings: PCORI s Model for Comparative Clinical Effectiveness Research
Research in Real-World Settings: PCORI s Model for Comparative Clinical Effectiveness Research David Hickam, MD, MPH Director, Clinical Effectiveness & Decision Science Program April 10, 2017 Welcome!
More informationThe Adoption of Evidence Khaled El Emam University of Ottawa
The Adoption of Evidence Khaled El Emam University of Ottawa Background Software engineering research for many years Health informatics in 2001 TrialStat SRS v1.2-2 Do We Really Need Evidence? Some things
More informationLecture Outline Biost 517 Applied Biostatistics I. Statistical Goals of Studies Role of Statistical Inference
Lecture Outline Biost 517 Applied Biostatistics I Scott S. Emerson, M.D., Ph.D. Professor of Biostatistics University of Washington Statistical Inference Role of Statistical Inference Hierarchy of Experimental
More informationBayesian Joint Modelling of Benefit and Risk in Drug Development
Bayesian Joint Modelling of Benefit and Risk in Drug Development EFSPI/PSDM Safety Statistics Meeting Leiden 2017 Disclosure is an employee and shareholder of GSK Data presented is based on human research
More informationInternational Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
Final Concept Paper E9(R1): Addendum to Statistical Principles for Clinical Trials on Choosing Appropriate Estimands and Defining Sensitivity Analyses in Clinical Trials dated 22 October 2014 Endorsed
More informationDecision Making in Confirmatory Multipopulation Tailoring Trials
Biopharmaceutical Applied Statistics Symposium (BASS) XX 6-Nov-2013, Orlando, FL Decision Making in Confirmatory Multipopulation Tailoring Trials Brian A. Millen, Ph.D. Acknowledgments Alex Dmitrienko
More informationComparing treatments evaluated in studies forming disconnected networks of evidence: A review of methods
Comparing treatments evaluated in studies forming disconnected networks of evidence: A review of methods John W Stevens Reader in Decision Science University of Sheffield EFPSI European Statistical Meeting
More informationExpanding the Toolkit: The Potential for Bayesian Methods in Education Research (Symposium)
Expanding the Toolkit: The Potential for Bayesian Methods in Education Research (Symposium) Symposium Abstract, SREE 2017 Spring Conference Organizer: Alexandra Resch, aresch@mathematica-mpr.com Symposium
More informationDrug Supply for Adaptive Trials
Drug Supply for Adaptive Trials Nitin R Patel Co-founder and Chairman, Cytel Inc. Outline Challenge of planning drug supply for adaptive trials Combining statistical design simulation with drug supply
More informationCoherence and calibration: comments on subjectivity and objectivity in Bayesian analysis (Comment on Articles by Berger and by Goldstein)
Bayesian Analysis (2006) 1, Number 3, pp. 423 428 Coherence and calibration: comments on subjectivity and objectivity in Bayesian analysis (Comment on Articles by Berger and by Goldstein) David Draper
More informationEXTRAPOLATION CHALLENGES IN PEDIATRIC PAH
EXTRAPOLATION CHALLENGES IN PEDIATRIC PAH Possible solutions for a feasible, global study M. Bacchi, A. Morganti, P. Cornelisse, J. Bolognese, C. Lesage, A. Kümmel, P. Nilsson Copyright 2016 Actelion Pharmaceuticals
More informationEconomic issues in Hepatitis C. Richard Grieve London School of Hygiene and Tropical Medicine
Economic issues in Hepatitis C Richard Grieve London School of Hygiene and Tropical Medicine Acknowledgements Mild Hepatitis C study Principal Investigators: Howard Thomas, Janice Main Centre co-ordinators
More informationI. Methods of Sociology Because sociology is a science as well as being a theoretical discipline, it is important to know the ways in which
I. Methods of Sociology Because sociology is a science as well as being a theoretical discipline, it is important to know the ways in which sociologists study society scientifically when they do research
More informationLecture 5 Conducting Interviews and Focus Groups
Lecture 5 Conducting Interviews and Focus Groups Talking to participants enables in-depth information about the experiences of health and illness; and of factors that influence health and illness behaviour
More informationOutline. What is Evidence-Based Practice? EVIDENCE-BASED PRACTICE. What EBP is Not:
Evidence Based Practice Primer Outline Evidence Based Practice (EBP) EBP overview and process Formulating clinical questions (PICO) Searching for EB answers Trial design Critical appraisal Assessing the
More informationOn the Utility of Subgroup Analyses in Confirmatory Clinical Trials
On the Utility of Subgroup Analyses in Confirmatory Clinical Trials EMA Expert Workshop on Subgroup Analyses 7-Nov-2014 Brian A. Millen, Ph.D. Outline Classification of Subgroup Analyses from Confirmatory
More informationInnovative Analytic Approaches in the Context of a Global Pediatric IBD Drug Development
Innovative Analytic Approaches in the Context of a Global Pediatric IBD Drug Development Margaret Gamalo-Siebers, PhD Global Statistical Sciences, Eli Lilly & Co. Pediatric Inflammatory Bowel Disease (IBD)
More informationLecturer: Dr. Adote Anum, Dept. of Psychology Contact Information:
Lecturer: Dr. Adote Anum, Dept. of Psychology Contact Information: aanum@ug.edu.gh College of Education School of Continuing and Distance Education 2014/2015 2016/2017 Session Overview The course provides
More informationReal-world data in pragmatic trials
Real-world data in pragmatic trials Harold C. Sox,MD The Patient-Centered Outcomes Research Institute Washington, DC Presenter Disclosure Information In compliance with the accrediting board policies,
More informationA Case Study: Two-sample categorical data
A Case Study: Two-sample categorical data Patrick Breheny January 31 Patrick Breheny BST 701: Bayesian Modeling in Biostatistics 1/43 Introduction Model specification Continuous vs. mixture priors Choice
More informationBayesian and Frequentist Approaches
Bayesian and Frequentist Approaches G. Jogesh Babu Penn State University http://sites.stat.psu.edu/ babu http://astrostatistics.psu.edu All models are wrong But some are useful George E. P. Box (son-in-law
More informationAbout the National Centre for Pharmacoeconomics
Cost effectiveness of sofosbuvir (in combination with either ribavirin or pegylated interferon + ribavirin) (Sovaldi ) for the treatment of hepatitis C infection The NCPE has issued a recommendation regarding
More informationPubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH
PubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH Instructor: Chap T. Le, Ph.D. Distinguished Professor of Biostatistics Basic Issues: COURSE INTRODUCTION BIOSTATISTICS BIOSTATISTICS is the Biomedical
More informationSTATS8: Introduction to Biostatistics. Overview. Babak Shahbaba Department of Statistics, UCI
STATS8: Introduction to Biostatistics Overview Babak Shahbaba Department of Statistics, UCI The role of statistical analysis in science This course discusses some biostatistical methods, which involve
More informationUNLOCKING VALUE WITH DATA SCIENCE BAYES APPROACH: MAKING DATA WORK HARDER
UNLOCKING VALUE WITH DATA SCIENCE BAYES APPROACH: MAKING DATA WORK HARDER 2016 DELIVERING VALUE WITH DATA SCIENCE BAYES APPROACH - MAKING DATA WORK HARDER The Ipsos MORI Data Science team increasingly
More informationEngagement of Individuals and Families in Early Psychosis Programs
Engagement of Individuals and Families in Early Psychosis Programs Tamara Sale, Director EASA Center for Excellence Portland State University tsale@pdx.edu www.easacommunity.org Dr. Douglas Noordsy Stanford
More informationEconometric analysis and counterfactual studies in the context of IA practices
Econometric analysis and counterfactual studies in the context of IA practices Giulia Santangelo http://crie.jrc.ec.europa.eu Centre for Research on Impact Evaluation DG EMPL - DG JRC CRIE Centre for Research
More informationMCQ Course in Pediatrics Al Yamamah Hospital June Dr M A Maleque Molla, FRCP, FRCPCH
MCQ Course in Pediatrics Al Yamamah Hospital 10-11 June Dr M A Maleque Molla, FRCP, FRCPCH Q1. Following statements are true in the steps of evidence based medicine except ; a) Convert the need for information
More informationUNIT 5 - Association Causation, Effect Modification and Validity
5 UNIT 5 - Association Causation, Effect Modification and Validity Introduction In Unit 1 we introduced the concept of causality in epidemiology and presented different ways in which causes can be understood
More informationDesign and analysis of clinical trials
Design and analysis of clinical trials Lecture 3 1.Basic Design Considerations 2.Sample Size determinationa 3.Randomization 2018-01-31 Previous Lectures Definition of a clinical trial The drug development
More informationProject Funded under FP7 - HEALTH Grant Agreement no Funded under FP7 - HEALTH Grant Agreement no
Developing methods of HTA for medical devices: WP3 - Methods for comparative effectiveness research of medical devices Final Conference November, 13 th 2015 U. Siebert, P. Schnell-Inderst, C. Iglesias,
More informationModelling heterogeneity variances in multiple treatment comparison meta-analysis Are informative priors the better solution?
Thorlund et al. BMC Medical Research Methodology 2013, 13:2 RESEARCH ARTICLE Open Access Modelling heterogeneity variances in multiple treatment comparison meta-analysis Are informative priors the better
More informationSchool of Population and Public Health SPPH 503 Epidemiologic methods II January to April 2019
School of Population and Public Health SPPH 503 Epidemiologic methods II January to April 2019 Time: Tuesday, 1330 1630 Location: School of Population and Public Health, UBC Course description Students
More informationSafeguarding public health CHMP's view on multiplicity; through assessment, advice and guidelines
Safeguarding public health CHMP's view on multiplicity; through assessment, advice and guidelines Rob Hemmings Statistics Unit Manager, MHRA CHMP member Chair, CHMP Scientific Advice Working Party Biostatistics
More information"PRINCIPLES OF PHYLOGENETICS: ECOLOGY AND EVOLUTION"
"PRINCIPLES OF PHYLOGENETICS: ECOLOGY AND EVOLUTION" Integrative Biology 200B University of California, Berkeley Lab for Jan 25, 2011, Introduction to Statistical Thinking A. Concepts: A way of making
More informationSOCQ121/BIOQ121. Session 8. Methods and Methodology. Department of Social Science. endeavour.edu.au
SOCQ121/BIOQ121 Session 8 Methods and Methodology Department of Social Science endeavour.edu.au Endeavour College of Natural Health endeavour.edu.au 1 Review Progress report to the person next to you on
More informationHow Does Analysis of Competing Hypotheses (ACH) Improve Intelligence Analysis?
How Does Analysis of Competing Hypotheses (ACH) Improve Intelligence Analysis? Richards J. Heuer, Jr. Version 1.2, October 16, 2005 This document is from a collection of works by Richards J. Heuer, Jr.
More informationSupplementary notes for lecture 8: Computational modeling of cognitive development
Supplementary notes for lecture 8: Computational modeling of cognitive development Slide 1 Why computational modeling is important for studying cognitive development. Let s think about how to study the
More informationUsing historical data for Bayesian sample size determination
Using historical data for Bayesian sample size determination Author: Fulvio De Santis, J. R. Statist. Soc. A (2007) 170, Part 1, pp. 95 113 Harvard Catalyst Journal Club: December 7 th 2016 Kush Kapur,
More informationDiscussion Meeting for MCP-Mod Qualification Opinion Request. Novartis 10 July 2013 EMA, London, UK
Discussion Meeting for MCP-Mod Qualification Opinion Request Novartis 10 July 2013 EMA, London, UK Attendees Face to face: Dr. Frank Bretz Global Statistical Methodology Head, Novartis Dr. Björn Bornkamp
More informationPractical Bayesian Design and Analysis for Drug and Device Clinical Trials
Practical Bayesian Design and Analysis for Drug and Device Clinical Trials p. 1/2 Practical Bayesian Design and Analysis for Drug and Device Clinical Trials Brian P. Hobbs Plan B Advisor: Bradley P. Carlin
More informationHow to design Homeopathy clinical randomised trials that
How to design Homeopathy clinical randomised trials that work Dr Clare Relton BA, MSc, PhD, FSHom Research Fellow School of Health & Related Research (ScHARR) Homeopathy & trials Myths Only evidence required
More informationNASH Regulatory Landscape. Veronica Miller, PhD Forum for Collaborative Research UC Berkeley SPH
NASH Regulatory Landscape Veronica Miller, PhD Forum for Collaborative Research UC Berkeley SPH Disclosures Liver Forum sponsors (last slides) Advisory (Sanofi) Miller_July 7_2017 www.forumresearch.org
More informationSRDC Technical Paper Series How Random Must Random Assignment Be in Random Assignment Experiments?
SRDC Technical Paper Series 03-01 How Random Must Random Assignment Be in Random Assignment Experiments? Paul Gustafson Department of Statistics University of British Columbia February 2003 SOCIAL RESEARCH
More informationMyers/Briggs Personality, Inventory Description in Workplace Communication
Myers/Briggs Personality, Inventory Description in Workplace Communication Effects of Preferences in Work Situations EXTRAVERSION INTROVERSION LIKE VARIETY AND ACTION LIKE QUIET FOR CONCENTRATION OFTEN
More informationThe Evidence Is So Clear. The Evidence Is So Clear
The Evidence Is So Clear 1 Evidence-Based Medicine is at the Heart of DynaMed Plus As described by Izet Masic, Milan Miokovic and Belma Muhamedagic, evidence-based medicine (EBM) is, the conscientious,
More informationIrrationality in Game Theory
Irrationality in Game Theory Yamin Htun Dec 9, 2005 Abstract The concepts in game theory have been evolving in such a way that existing theories are recasted to apply to problems that previously appeared
More informationLecture 4: Research Approaches
Lecture 4: Research Approaches Lecture Objectives Theories in research Research design approaches ú Experimental vs. non-experimental ú Cross-sectional and longitudinal ú Descriptive approaches How to
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationM6728. Goals. Depression Scores. Research Designs
M6728 Research Designs Goals Match appropriate research designs to the study purpose and questions Differentiate between experimental and non-experimental studies Discuss epidemiologic designs Evaluate
More informationAnalysis methods for improved external validity
Analysis methods for improved external validity Elizabeth Stuart Johns Hopkins Bloomberg School of Public Health Department of Mental Health Department of Biostatistics www.biostat.jhsph.edu/ estuart estuart@jhsph.edu
More informationBayesian Benefit-Risk Assessment. Maria Costa GSK R&D
Assessment GSK R&D Disclosure is an employee and shareholder of GSK Data presented is based on human research studies funded and sponsored by GSK 2 Outline 1. Motivation 2. GSK s Approach to Benefit-Risk
More informationGATE: Graphic Appraisal Tool for Epidemiology picture, 2 formulas & 3 acronyms
GATE: Graphic Appraisal Tool for Epidemiology 1991-2015 1 picture, 2 formulas & 3 acronyms 1 GATE: Graphic Appraisal Tool for Epidemiology Graphic Architectural Tool for Epidemiology Graphic Approach To
More informationVocabulary. Bias. Blinding. Block. Cluster sample
Bias Blinding Block Census Cluster sample Confounding Control group Convenience sample Designs Experiment Experimental units Factor Level Any systematic failure of a sampling method to represent its population
More informationFlex:upgrade counsel guide 1.0
Flex:upgrade counsel guide 1.0 This guide is divided into the following sections for easy reference: 1For patients motivated to experience more 2 3 Clinical and business impacts of Flex:upgrade Helping
More informationUsing Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs
Using Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs David Manner, Brenda Crowe and Linda Shurzinske BASS XVI November 9-13, 2009 Acknowledgements
More informationCareer Research and Development. Self-Awareness Unit Personality Type
Career Research and Development Self-Awareness Unit Personality Type 1 Objectives: Students will be able to: 1. Identify their personality type and explain how it influences career choices. 2. Explain
More informationHow to use the Lafayette ESS Report to obtain a probability of deception or truth-telling
Lafayette Tech Talk: How to Use the Lafayette ESS Report to Obtain a Bayesian Conditional Probability of Deception or Truth-telling Raymond Nelson The Lafayette ESS Report is a useful tool for field polygraph
More informationFull title: A likelihood-based approach to early stopping in single arm phase II cancer clinical trials
Full title: A likelihood-based approach to early stopping in single arm phase II cancer clinical trials Short title: Likelihood-based early stopping design in single arm phase II studies Elizabeth Garrett-Mayer,
More informationResponse to the ASA s statement on p-values: context, process, and purpose
Response to the ASA s statement on p-values: context, process, purpose Edward L. Ionides Alexer Giessing Yaacov Ritov Scott E. Page Departments of Complex Systems, Political Science Economics, University
More informationGSK Proposed Phase 2 Program for ChAd3 EBOV Vaccine Candidate
GSK Proposed Phase 2 Program for ChAd3 EBOV Vaccine Candidate Vaccine availability for Phase 2 program Dependent upon: Dose level selected in Phase 1 Productivity of the current manufacturing process (at
More informationSystematic Reviews and Meta- Analysis in Kidney Transplantation
Systematic Reviews and Meta- Analysis in Kidney Transplantation Greg Knoll MD MSc Associate Professor of Medicine Medical Director, Kidney Transplantation University of Ottawa and The Ottawa Hospital KRESCENT
More informationHepatitis C: Ribavirin/Pegylated Interferon combination therapy
Hepatitis C: Ribavirin/Pegylated Interferon Introduction This information sheet is for people who want to know more about the ribavirin/pegylated interferon combination treatment for Hepatitis C (HCV).
More informationDr. Gigi Osler Inaugural address Dr. Gigi Osler President Canadian Medical Association Winnipeg, Man. August 22, 2018 Check against delivery
Speech Dr. Gigi Osler Inaugural address Dr. Gigi Osler President Canadian Medical Association Winnipeg, Man. August 22, 2018 Check against delivery Good morning everyone and thank you. Before I begin,
More informationNew Challenges: Model-based Dose Finding in the Era of Targeted Agents
New Challenges: Model-based Dose Finding in the Era of Targeted Agents Elizabeth Garrett-Mayer, PhD 1 Cody Chiuzan, PhD 2 1 Hollings Cancer Center Department of Public Health Sciences Medical University
More informationHans Hockey & Kristian Brock Biometrics Matters Ltd, Hamilton, NZ & Cancer Research UK Clinical Trials Unit, Birmingham, UK
HOCKEY STICKS AND BROKEN STICKS A DESIGN FOR A SINGLE-TREATMENT, PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL SUITABLE FOR CHRONIC DISEASES Hans Hockey & Kristian Brock Biometrics Matters
More informationChapter 02 Developing and Evaluating Theories of Behavior
Chapter 02 Developing and Evaluating Theories of Behavior Multiple Choice Questions 1. A theory is a(n): A. plausible or scientifically acceptable, well-substantiated explanation of some aspect of the
More informationDesign for Targeted Therapies: Statistical Considerations
Design for Targeted Therapies: Statistical Considerations J. Jack Lee, Ph.D. Department of Biostatistics University of Texas M. D. Anderson Cancer Center Outline Premise General Review of Statistical Designs
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationRegulatory interactions: Expectations on extrapolation approaches
Regulatory interactions: Expectations on extrapolation approaches Lynne Yao, M.D. Director, Division of Pediatric and Maternal Health Office of New Drugs Center for Drug Evaluation and Research U.S. Food
More informationTechnology appraisal guidance Published: 23 March 2016 nice.org.uk/guidance/ta386
Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis Technology appraisal guidance Published: 23 March 2016 nice.org.uk/guidance/ta386 NICE 2017. All rights reserved.
More informationA Brief Introduction to Bayesian Statistics
A Brief Introduction to Statistics David Kaplan Department of Educational Psychology Methods for Social Policy Research and, Washington, DC 2017 1 / 37 The Reverend Thomas Bayes, 1701 1761 2 / 37 Pierre-Simon
More informationSafeguarding public health Subgroup Analyses: Important, Infuriating and Intractable
Safeguarding public health Subgroup Analyses: Important, Infuriating and Intractable The views expressed herein are not necessarily those of MHRA, EMA, EMA committees or their working parties. Rob Hemmings
More informationWhich of the following are potential negative outcomes pharmacists face due to medication counseling?
"Cash-Register Counseling - Pharmacists Perspectives on Communication Across the Counter: A Study from the Medication Safety Research Network of Indiana (Rx-SafeNet) Jaclyn R. Myers, PharmD, PhD Candidate
More informationBehavioral EQ MULTI-RATER PROFILE. Prepared for: By: Session: 22 Jul Madeline Bertrand. Sample Organization
Behavioral EQ MULTI-RATER PROFILE Prepared for: Madeline Bertrand By: Sample Organization Session: Improving Interpersonal Effectiveness 22 Jul 2014 Behavioral EQ, Putting Emotional Intelligence to Work,
More informationCochrane Pregnancy and Childbirth Group Methodological Guidelines
Cochrane Pregnancy and Childbirth Group Methodological Guidelines [Prepared by Simon Gates: July 2009, updated July 2012] These guidelines are intended to aid quality and consistency across the reviews
More informationA case study design of adaptive dose selection in a combined Phase II/III clinical trial. Junliang Chen, Ph.D November 18, 2016
A case study design of adaptive dose selection in a combined Phase II/III clinical trial Junliang Chen, Ph.D November 18, 2016 1 Outlines: Background Study design Statistical considerations Operational
More informationIs therapy a realistic option at the present time? Felipe Fregni LEASE DO NOT COPY. Spauding Neuromodulation Center Harvard Medical School
Is therapy a realistic option at the present time? Felipe Fregni Spauding Neuromodulation Center Harvard Medical School Arguments supporting therapeutic use of tdcs Questions to be answered: Is there a
More informationMarket Access in Hepatitis C Learnings From HIV
Market Access in Hepatitis C Learnings From HIV Allan F. Miranda Ph.D., MBA. Therapeutic Lead Immunology and Virology- Government Affairs and Market Access Our CREDO Throughout our global organization
More informationSTUDY DESIGNS WHICH ONE IS BEST?
STUDY DESIGNS WHICH ONE IS BEST? David Nunan, PhD Research Fellow and Tutor Nuffield Department of Primary Care Health Sciences and Oxford Centre for Evidence Based Medicine University of Oxford Exercise
More informationT-Statistic-based Up&Down Design for Dose-Finding Competes Favorably with Bayesian 4-parameter Logistic Design
T-Statistic-based Up&Down Design for Dose-Finding Competes Favorably with Bayesian 4-parameter Logistic Design James A. Bolognese, Cytel Nitin Patel, Cytel Yevgen Tymofyeyef, Merck Inna Perevozskaya, Wyeth
More informationDesigning a Bayesian randomised controlled trial in osteosarcoma. How to incorporate historical data?
Designing a Bayesian randomised controlled trial in osteosarcoma: How to incorporate historical data? C. Brard, L.V Hampson, M-C Le Deley, G. Le Teuff SCT - Montreal, May 18th 2016 Brard et al. Designing
More informationPhysiological Function, Health and Medical Theory
Physiological Function, Health and Medical Theory Amanda Thorell PhD-student at the Department of Philosophy, Stockholm University amanda.thorell@philosophy.su.se Abstract In medicine, the concepts of
More informationUnderstanding Science Conceptual Framework
1 Understanding Science Conceptual Framework This list of conceptual understandings regarding the nature and process of science are aligned across grade levels to help instructors identify age-appropriate
More informationHow to do a quick search for evidence
bs_bs_banner doi:10.1111/jpc.12514 VIEWPOINT David Isaacs Department of Infectious Diseases & Microbiology, Children s Hospital at Westmead, Sydney, New South Wales, Australia Abstract: Doctors quote lack
More informationClinically Meaningful Inclusion of Participants in Clinical Trials. David Hickam, MD, MPH Washington, DC April 9, 2015
Clinically Meaningful Inclusion of Participants in Clinical Trials David Hickam, MD, MPH Washington, DC April 9, 2015 Key Questions for this Presentation What are the important features of patient centered
More informationPTHP 7101 Research 1 Chapter Assignments
PTHP 7101 Research 1 Chapter Assignments INSTRUCTIONS: Go over the questions/pointers pertaining to the chapters and turn in a hard copy of your answers at the beginning of class (on the day that it is
More informationTechnology appraisal guidance Published: 24 January 2018 nice.org.uk/guidance/ta499
Glecaprevir pibrentasvir for treating chronic hepatitis C Technology appraisal guidance Published: 24 January 2018 nice.org.uk/guidance/ta499 NICE 2018. All rights reserved. Subject to Notice of rights
More informationPsych 1Chapter 2 Overview
Psych 1Chapter 2 Overview After studying this chapter, you should be able to answer the following questions: 1) What are five characteristics of an ideal scientist? 2) What are the defining elements of
More informationChapter 5: Producing Data
Chapter 5: Producing Data Key Vocabulary: observational study vs. experiment confounded variables population vs. sample sampling vs. census sample design voluntary response sampling convenience sampling
More informationWhat role should formal riskbenefit decision-making play in the regulation of medicines?
What role should formal riskbenefit decision-making play in the regulation of medicines? Deborah Ashby Dept of Epidemiology and Public Health Imperial College London Outline Decision-making: statistical
More informationChoosing the right study design
Choosing the right study design Main types of study design Randomised controlled trial (RCT) Cohort study Case-control study Cross-sectional study Case series/case note review Expert opinion BEST QUALITY
More informationHow to Choose the Wrong Model. Scott L. Zeger Department of Biostatistics Johns Hopkins Bloomberg School
How to Choose the Wrong Model Scott L. Zeger Department of Biostatistics Johns Hopkins Bloomberg School What is a model? Questions Which is the best (true, right) model? How can you choose a useful model?
More information10/21/2014. Considerations in the Selection of Research Participants. Reasons to think about participant selection
Considerations in the Selection of Research Participants Catherine M. Stoney, Ph.D. National Heart, Lung, and Blood Institute Introduction to the Principles & Practice of Clinical Research October 21,
More informationTITLE: Re-treatment with Direct Acting Antivirals for Chronic Hepatitis C Genotype 1: Emerging Evidence of Clinical Effectiveness and Safety An Update
TITLE: Re-treatment with Direct Acting Antivirals for Chronic Hepatitis C Genotype 1: Emerging Evidence of Clinical Effectiveness and Safety An Update DATE: 02 January 2015 RESEARCH QUESTION What is the
More information